Promising combo for rare breast cancer subtype hits early snag
Disease control
Terminated
This early-phase trial tested a combination of two drugs—infigratinib (a targeted therapy) and tamoxifen (a hormone therapy)—in people with a specific type of advanced breast cancer (hormone receptor-positive, HER2-negative, with FGFR gene changes). The goal was to find a safe do…
Phase: PHASE1 • Sponsor: Jennifer Lee Caswell-Jin • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC